Skip to main content
Loading...

Identification of a 1,2,4,5-Tetraoxane Antimalarial Drug-Development Candidate

From a library of over 150 1,2,4,5‐tetraoxanes, the candidate RKA 182 was selected for preclinical development as an antimalarial agent.

Tuesday, 31 March 2020

From a library of over 150 1,2,4,5‐tetraoxanes, the candidate RKA 182 was selected for preclinical development as an antimalarial agent. RKA 182 has outstanding in vitro activity against resistant strains of P. falciparum and retains this level of activity against southeast asian isolates that failed artemisinin‐based combination therapy.

 
×

Thank you for your interest!

Before you download can we get some information?
* I agree to the Terms and Conditions.